Back to top
more

Fate Therapeutics, Inc. (FATE)

(Delayed Data from NSDQ)

$80.14 USD

80.14
959,244

-2.87 (-3.46%)

Updated Jul 27, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 18% (206 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Why Is Fate Therapeutics (FATE) Down 12.2% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues

FATE reports a wider Q1 loss on increased R&D expenses.

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Down 9% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses

FATE reports a wider Q4 loss on increased R&D expenses.

Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

Kinjel Shah headshot

CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.

Is the Options Market Predicting a Spike in Fate Therapeutics (FATE) Stock?

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics

The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics

Kinjel Shah headshot

5 Biotech Stocks That Have Gained More Than 200% in 2020

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

FATE Surges More Than 152% in Three Months: Here's Why?

FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.

Ekta Bagri headshot

5 Biotech Stocks That More Than Doubled This Year

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News

Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.

Fate Therapeutics (FATE) Looks Good: Stock Adds 9.4% in Session

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH

Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.

Why Is Fate Therapeutics (FATE) Up 21.8% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fate's IND Application for CAR T Cell Therapy Gets FDA Nod

Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -15.79% and 21.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?

Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.